Tissue Regenix Group Statistics

Total Valuation

Tissue Regenix Group has a market cap or net worth of GBP 42.03 million. The enterprise value is 47.02 million.

Market Cap	42.03M
Enterprise Value	47.02M

Important Dates

The next estimated earnings date is Wednesday, December 11, 2024.

Earnings Date	Dec 11, 2024
Ex-Dividend Date	n/a

Share Statistics

Tissue Regenix Group has 71.23 million shares outstanding. The number of shares has increased by 0.27% in one year.

Current Share Class	n/a
Shares Outstanding	71.23M
Shares Change (YoY)	+0.27%
Shares Change (QoQ)	+0.14%
Owned by Insiders (%)	28.60%
Owned by Institutions (%)	42.32%
Float	39.75M

Valuation Ratios

PE Ratio	n/a
Forward PE	245.83
PS Ratio	1.65
PB Ratio	1.75
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 43.06, with an EV/FCF ratio of -600.30.

EV / Earnings	-53.98
EV / Sales	1.87
EV / EBITDA	43.06
EV / EBIT	163.72
EV / FCF	-600.30

Financial Position

The company has a current ratio of 3.74, with a Debt / Equity ratio of 0.36.

Current Ratio	3.74
Quick Ratio	1.47
Debt / Equity	0.36
Debt / EBITDA	7.59
Debt / FCF	-105.78
Interest Coverage	0.39

Financial Efficiency

Return on equity (ROE) is -3.31% and return on invested capital (ROIC) is 0.57%.

Return on Equity (ROE)	-3.31%
Return on Assets (ROA)	0.50%
Return on Capital (ROIC)	0.57%
Revenue Per Employee	306,829
Profits Per Employee	-10,624
Employee Count	82
Asset Turnover	0.71
Inventory Turnover	1.33

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +7.77% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+7.77%
50-Day Moving Average	57.36
200-Day Moving Average	62.80
Relative Strength Index (RSI)	46.98
Average Volume (20 Days)	71,123

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tissue Regenix Group had revenue of GBP 25.16 million and -871,188 in losses. Loss per share was -0.01.

Revenue	25.16M
Gross Profit	12.45M
Operating Income	287,231
Pretax Income	-485,840
Net Income	-871,188
EBITDA	981,966
EBIT	287,231
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 2.74 million in cash and 8.29 million in debt, giving a net cash position of -5.55 million or -0.08 per share.

Cash & Cash Equivalents	2.74M
Total Debt	8.29M
Net Cash	-5.55M
Net Cash Per Share	-0.08
Equity (Book Value)	23.22M
Book Value Per Share	0.34
Working Capital	12.14M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 283,275 and capital expenditures -361,610, giving a free cash flow of -78,335.

Operating Cash Flow	283,275
Capital Expenditures	-361,610
Free Cash Flow	-78,335
FCF Per Share	-0.00

Full Cash Flow Statement

Margins

Gross margin is 49.48%, with operating and profit margins of 1.14% and -3.46%.

Gross Margin	49.48%
Operating Margin	1.14%
Pretax Margin	-1.93%
Profit Margin	-3.46%
EBITDA Margin	3.90%
EBIT Margin	1.14%
FCF Margin	-0.31%

Dividends & Yields

Tissue Regenix Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.27%
Shareholder Yield	-0.27%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on April 28, 2023. It was a reverse split with a ratio of 0.01.

Last Split Date	Apr 28, 2023
Split Type	Reverse
Split Ratio	0.01

Scores

Tissue Regenix Group has an Altman Z-Score of -0.73. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.73
Piotroski F-Score	n/a